Triphenylethylene compounds as dual aromatase inhibitors and selective estrogen receptors modulators are described. Also described are methods for treating patients of breast cancers, and patients of breast cancer comorbid with osteoporosis, using the described triphenylethylence compounds or pharmaceutical formulations thereof.
A new Suzuki synthesis of triphenylethylenes that inhibit aromatase and bind to estrogen receptors α and β
作者:Li-Ming Zhao、Hai-Shan Jin、Jinzhong Liu、Todd C. Skaar、Joseph Ipe、Wei Lv、David A. Flockhart、Mark Cushman
DOI:10.1016/j.bmc.2016.08.064
日期:2016.11
The design and synthesis of dual aromataseinhibitors/selective estrogen receptor modulators (AI/SERMs) is an attractive strategy for the discovery of new breast cancer therapeutic agents. Previous efforts led to the preparation of norendoxifen (4) derivatives with dual aromatase inhibitory activity and estrogen receptor binding activity. In the present study, some of the structural features of the